STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #834 by analyst upside · 2026-06-27
PTHS
Pelthos Therapeutics Inc.
Healthcare · Market Cap $101M · P/E 0x
ANALYST PRICE TARGET
+98.8%
implied upside to consensus target
Current Price $29.03
Consensus Target $57.71
Bull Target $75.0
Bear Target $48.0
Analysts Covering 7
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
6
Hold
0
Sell
0
52-Week Low $11.21
52-Week High $54.29
YTD Return -1.4%
FUNDAMENTALS
Market Cap $101M
P/E Ratio (TTM) N/A
Forward P/E -13.7x
EPS (TTM) $-22.78
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $28M
Profit Margin -186.2%
52-WEEK RANGE
52-Week Low $11.21
52-Week High $54.29
Current Price $29.03
Bear Target $48.0
Bull Target $75.0
● Now $29.03 ● Target $57.71
TRADING DATA
Avg Volume 20K
YTD Return -1.4%
Analyst Count 7
Consensus Buy
Upside to Target +98.8%
Last Updated 2026-06-27

ANALYST SUMMARY

Pelthos Therapeutics Inc. (PTHS) is currently trading at $29.03 with a Wall Street consensus price target of $57.71, implying potential upside of 98.8% over the next 12 months. 7 analysts currently cover PTHS, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $75.0, while the most cautious has a target of $48.0.

PTHS operates in the Healthcare sector with a market capitalisation of $101M. The stock is down 1.4% year-to-date and is currently trading near the lower end of its 52-week range of $11.21 – $54.29.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PTHS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer — Reiterated
Outperform → Outperform 2026-05-15 14% win rate (7 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-04-01 40% win rate (10 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2026-03-20 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-19 31% win rate (48 calls)
Piper Sandler ● Initiated
Overweight 2026-02-27 14% win rate (7 calls)
Roth Capital — Reiterated
Buy → Buy 2026-02-26 Building track record
Oppenheimer — Reiterated
Outperform → Outperform 2026-01-26 14% win rate (7 calls)
Lake Street ● Initiated
Buy 2025-12-03 27% win rate (11 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →